Astrocyte Pharmaceuticals, Inc.
Publicly observedCambridge, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Cambridge | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Astrocyte Pharmaceuticals, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | ZEP1G3FGYUP3 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Jul 2026Publicly observed
NIH SBIR/STTR award: Preclinical efficacy of AST-004 as a treatment for substance use disorder
USD 399,680.00 · National Institute on Drug Abuse · Source: NIH RePORTER (opens in a new tab)
- Grant12 Jun 2025Publicly observed
NIH SBIR/STTR award: Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)
USD 1,499,802.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant12 Jun 2025Publicly observed
NIH SBIR/STTR award: Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)
USD 1,499,886.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.